Innovent and HUTCHMED Say FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint Mar 18, 2025 08:57PM
Innovent and Eli Lilly Expand Collaboration Dec 15, 2024 06:57PM